News

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
PharmExec4d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
CIDRAP7d
FDA approves Merck RSV monoclonal antibody shot for infants
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...
WCPO 9 News4d
FDA approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
MedCity News8d
Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted
A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA ... vaccine comprised of an engineered version of RSV F protein antigen. It was first ...
Zacks.com on MSN7d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.